<DOC>
	<DOCNO>NCT00860288</DOCNO>
	<brief_summary>This 2-3 period parallel group study adaptive element Type 2 diabetes patient receive vildagliptin add-on therapy metformin</brief_summary>
	<brief_title>Efficacy Long-Term Safety Vildagliptin Add-on Therapy Metformin Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients 1878 year old inclusive Visit 1 T2DM patient treat metformin least 3 month stable dose least 1500 mg daily minimum 4 week prior Visit 1 Patient agreement maintain dose metformin throughout study HbA1c ≥ 7.0 ≤ 9.5 % Visit 1 Body Mass Index ( BMI ) range 2245 kg/m2 visit 1 Pregnant nursing ( lactate ) woman FPG ≥ 270 mg/dL ( ≥ 15.0 mmol/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>vildagliptin</keyword>
</DOC>